Donepezil Hydrochloride (Aricept)

ApprovedWithdrawn
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Severe Alzheimer's Disease

Conditions

Severe Alzheimer's Disease

Trial Timeline

Jan 1, 2008 โ†’ โ€”

About Donepezil Hydrochloride (Aricept)

Donepezil Hydrochloride (Aricept) is a approved stage product being developed by Eisai for Severe Alzheimer's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00711204. Target conditions include Severe Alzheimer's Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT00675025Phase 2Terminated
NCT00711204ApprovedWithdrawn
NCT00165763ApprovedCompleted

Competing Products

20 competing products in Severe Alzheimer's Disease

See all competitors